|
|
Vaccine Detail
|
HLA-A2, A3-Restricted FGF-5 Peptides/Montanide ISA-51 Vaccine |
| Vaccine Information |
- Vaccine Name: HLA-A2, A3-Restricted FGF-5 Peptides/Montanide ISA-51 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007565
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: FGF5
- FGF5
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: A peptide vaccine comprised of synthetic HLA-A2- and HLA-A3-binding peptides, derived from amino acid sequences of fibroblast growth factor-5 (FGF-5), combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. HLA-A2, A3-restricted FGF-5 peptides contain motifs recognized by the MHC class I molecules HLA-A2 and HLA-A3 and may stimulate a cytotoxic T-cell response against tumor cells that overexpress FGF-5. Montanide ISA-51, a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant, non-specifically stimulates cell-mediated immune responses to antigens. (NCIT_C48394).
|
| Host Response |
|
|
| References |
NCIT_C48394: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48394]
|
|
